There are 511 resources available
89P - Real-world study of late-line treatment regimens for metastatic colorectal cancer (mCRC): A multi-cohort, propensity-matched analysis
Presenter: Wangxia Lv
Session: Poster Display session
Resources:
Abstract
90P - Predictive and prognostic factors in metastatic colorectal cancer patients treated with fruquintinib: A multicenter real-world analysis
Presenter: Chen Zhang
Session: Poster Display session
Resources:
Abstract
91P - Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
Presenter: Josep Tabernero
Session: Poster Display session
Resources:
Abstract
92P - Minor RAS mutations as predictors of survival in recurrent or metastatic colorectal cancer: A retrospective study in a single institution
Presenter: Yoshiki Kojitani
Session: Poster Display session
Resources:
Abstract
93P - Trifluridine-Tipiracil (FTD/TPI) plus Bevacizumab (BV) in patients (pts) with pretreated metastatic colorectal cancer (mCRC): a real-life Italian multicenter experience.
Presenter: Giovanni Trovato
Session: Poster Display session
Resources:
Abstract
94P - Stereotactic body radiotherapy (SBRT) as radical treatment for lung metastases of colorectal cancer: A single-center study
Presenter: Mehmet Varol
Session: Poster Display session
Resources:
Abstract
95P - Partial cystectomy may be a feasible procedure in colorectal cancer patients with clinically diagnosed bladder invasion: An original retrospective study
Presenter: Bing Lan
Session: Poster Display session
Resources:
Abstract
96P - Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer: A gender-disaggregated analysis
Presenter: Laura Pala
Session: Poster Display session
Resources:
Abstract
97P - Circulating serum and tumor gene expression level of lactate dehydrogenase in metastatic colorectal cancer
Presenter: Erman Akkus
Session: Poster Display session
Resources:
Abstract
98P - Intermittent first-line anti-EGFR with chemotherapy improves the survival of patients with RAS and BRAF wild type metastatic colon cancer
Presenter: Alice Dewdney
Session: Poster Display session
Resources:
Abstract